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Although vitamin D is included in the group of fat-sol-
uble vitamins, it must be considered as a prohormone. 
Its active forms, including calcitriol, have pleiotropic ef-
fects and play an important role in the regulation of cell 
proliferation, differentiation and apoptosis, as well as in 
hormone secretion, and they demonstrate anti-cancer 
properties. Since calcitriol delivery can be beneficial for 
the organism, and Syrian golden hamsters represent a 
unique experimental model, we decided to investigate 
its toxicity in this species. In this study, we injected cal-
citriol intraperitoneally at doses 0  (control), 0.180±0.009 
µg/kg and 0.717±0.032 µg/kg. Animal behavior was ob-
served for 72 hrs after injection, and afterwards blood, 
liver and kidneys were collected for post-mortem exam-
ination, electron microscopy, and hematology analyses. 
The highest dose of calcitriol induced a change in animal 
behavior from calm to aggressive, and the liver surface 
showed morphological signs of damage. Following in-
jection of calcitriol, ultrastructural changes were also ob-
served in the liver and kidneys, e.g. vacuolization and in-
creased number of mitochondria. There was also a trend 
for increased serum levels of aspartate aminotransferase 
(AST), but not of alanine aminotransferase (ALT) or GGTP 
(gamma-glutamyl transpeptidase). There was no change 
in Ca, Mg and P levels, as well as in blood morphology 
between experimental and control groups. These results 
indicate that calcitriol at 0.717, but not at 0.180 µg/kg, 
may induce acute damage to the liver and kidneys, with-
out inducing calcemia. We propose that the hepatotox-
ic effect of calcitriol in hamster constitutes the primary 
cause of behavioral changes.
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INTRODUCTION
Vitamin D is included in the group of fat-soluble vi-
tamins (Venkatram et al., 2011), but it is also considered 
to be the oldest hormone in the world associated with 
a good health status of people, as well as many other 
forms of life (Holick et al., 2007; Bikle, 2011; Christakos 
et al., 2016; Piotrowska et al., 2016). The functions of vi-
tamin D and its derivatives are associated not only with 
calcium and phosphorus homeostasis and the proper 
functioning of the skeletal system, but also with the reg-
ulation of many body systems, including the cardiovas-
cular, endocrine, immune, and central nervous systems 
as examples (Holick, 2007; Bikle, 2011; Christakos et al., 
2016; Rejnmark et al., 2017). The pleiotropic effect is re-
lated to the regulation of cell proliferation, differentiation 
and apoptosis, hormone secretion and other mechanisms 
(Samuel & Sitrin, 2008; Burns et al., 2015; Christakos et 
al., 2016; Piotrowska et al., 2016). Vitamin D is also de-
scribed in the literature as an anti-cancer agent (Holick, 
2007; Battault et al., 2013; Bikle et al., 2013; Slominski et 
al., 2014; Slominski et al., 2015a; Wierzbicka et al., 2014).
Vitamin D can be delivered to the body in a diet con-
taining cholecalciferol or ergocalciferol, but it is mainly 
obtained through skin phototransformation of 7-dehy-
drocholesterol under ultraviolet-B (UVB) radiation (Lips, 
2006; Holick, 2007; Bikle, 2011; Henry, 2011). Interest-
ingly, although vitamin D is important for many organ-
isms (Holick et al., 2007), most furry animals, including 
dogs, cats or rodents, are not able to effectively and ef-
ficiently produce vitamin D in the skin, hence diet is the 
primary source of this vitamin for them (Corbee et al., 
2008). The 7-dehydrocholesterol present in epidermal 
cells is transformed into pre-vitamin D3 by absorbing 
UVB energy by the unsaturated-B ring, and then after 
thermal reorganization, vitamin D3 is released into the 
bloodstream (Holick, 2003; Henry, 2011). After binding 
to the vitamin D Binding Protein (VDBP), it is trans-
ported to the liver, where it undergoes the first hydroxy-
lation by CYP2R1 or CYP27A1 to produce calcidiol 
(25(OH)D3), which is then transported to the kidneys, 
where it is hydroxylated to the active form of calcitriol 
(1,25(OH)2D3) (Reichrath et al., 2007; Lehmann & Meur-
er, 2010; Bikle, 2014). Alternative pathways of vitamin 
D activation by CYP11A1, a rate limiting enzyme of 
steroidogenesis, have recently been described (Slominski 
et al., 2005, 2012, 2015b, 2015c). The products of that 
pathway are biologically active, and act on vitamin D re-
ceptor (VDR) and retinoic orphan acid receptors (RORs) 
(Slominski et al., 2014; Slominski et al., 2017a; Slominski 
et al., 2017b).
Currently, it is estimated that vitamin D deficiency af-
fects up to one billion people around the world (Maza-
hery & Hurst, 2015). According to the Endocrine So-
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ciety (ES), it is assumed that deficiency corresponds 
to a 25(OH)D serum concentration below 20 ng/
ml (<50 nmol/L); serum level between 20 ng/ml (50 
nmol/L) and 30 ng/ml (<75 nmol/L) is considered as 
insufficiency; while levels above 30 ng/ml (>75 nmol/L) 
are sufficient to maintain normal physiological functions 
(Gupta et al., 2014; Sowah et al., 2017). Although the ac-
tive form of this vitamin is its metabolite 1,25(OH)2D3, 
the determination of the vitamin D status is not based 
on the measurement of its serum concentration (Thacher 
& Clarke, 2011). Metabolite 25(OH)D is used for that 
purpose, whose half-life in human serum is about 2–3 
weeks (Holick, 2009; Thacher & Clarke, 2011).
Interestingly, vitamin D toxicity (VDT), also known 
as hypervitaminosis D, is a rare complication (Marins et 
al., 2014; Marcinowska-Suchowierska et al., 2016). As our 
body can regulate the amount of vitamin D produced 
during sun exposure, and enriched foods do not contain 
large amounts of this compound (Gupta et al., 2014), 
poisoning will not occur because the excess of vitamin 
D3 and its precursor is photodegradable, as proposed 
by many authors (Alshahrani & Aljohani, 2013; Wacker 
& Holick, 2013). Vitamin D may also follow alterna-
tive pathways of activation in the skin or in organs ex-
pressing high systemic levels of CYP11A1 (Slominski et 
al., 2012; Slominski et al., 2015c; Slominski et al., 2018). 
However, excessive oral intake of artificial supplements 
may lead to such excess (Marins et al., 2014; Marcinow-
ska-Suchowierska et al., 2016). Especially nowadays, high 
doses of vitamin D are sold without prescription, which 
can lead to patients taking excessive amounts of vitamin 
D supplements (Gorris et al., 2016). The main and most 
frequently reported clinical consequence of vitamin D 
toxicity is hypercalcemia (Holick, 2007; Chakraborty et 
al., 2015). The probable mechanism of vitamin D tox-
icity is related to a signal transduction process, and the 
fact that the catabolic system and CYP24A1 are not able 
to keep up with the target calcitriol cell levels (Koul et 
al., 2011). Early symptoms of vitamin D toxicity include, 
among others, nausea, diarrhoea, anorexia, bone pain, 
drowsiness, constant headaches, irregular heartbeat and 
hypertension, loss of appetite, muscle and joint pain, and 
also nervousness (Schwalfenberg, 2007; Alshahrani & Al-
johani, 2013; Virmani, 2014).
Since an increased calcitriol uptake can be beneficial 
for organisms, we decided to study the toxicity of vita-
min D active form in hamsters. In our study we focused 
our interest on behavioral observation, hematology, in-
ternal organ function and morphology.
MATERIALS AND METHODS
Animals. This experiment was performed using 12 
female Syrian golden hamsters (22–23 months old) pur-
chased at the Charles River Laboratories. The experi-
ments on animals were approved by the Local Institu-
tional Animal Care and Use Committee, approval No. 
264/2015. The animals were maintained under sterile 
conditions in a ventilated cabin equipped with HEPA fil-
ters, in a 12 h light cycle, with free access to water and 
food. The detailed composition of the feed (the Labo-
feed B standard, Wytwornia Pasz “Morawski”, Kcynia, 
Poland) is presented in the Supplementary Fig. S1 (at 
www.actabp.pl).
Calcitriol treatment. Calcitriol (1,25(OH)2D3) was 
purchased from Sigma-Aldrich. First, vitamin D was 
dissolved in 100% ethanol to 100 µM. Then it was 
diluted in PBS to 50 nM (final ethanol concentration 
was 0.05%) and 200 nM (0.20% final ethanol concen-
tration) to a total injectable volume of 2 ml. The dos-
es of 50 nM and 200 nM calcitriol per kilogram body 
weight were 0.180 ± 0.009 µg/kg and 0.717 ± 0.032 µg/
kg, respectively. Four hamsters treated with the vehicle 
(PBS plus ethanol) served as controls. All injections were 
intraperitoneal. Animal behavior was recorded daily (the 
characteristic pain symptoms were under special inves-
tigation, e.g. the eye shape, fur condition, ear position, 
socialization, and hyperactivity), and the Syrian golden 
hamsters were euthanized 72 hours after 1,25(OH)2D3 
or vehicle administration.
Post-mortem examination. Syrian golden hamsters 
were euthanized by injection of a mixture of drugs 
(ketamine and xylazine, 150 mg/kg and 10 mg/kg, re-
spectively, ip injection). Their blood was drawn from the 
ventricles of a beating heart. The livers and kidneys were 
also collected, grossly inspected, weighed and prepared 
for further examination.
Tissue preparation for transmission electron mi-
croscopy. Tissue fragments were fixed in 3% glutaral-
dehyde, followed by contrasting with 2% OsO4 (SPI 
Supplies, USA), and then immersed in epoxy resin Epon 
812 (Serva, Germany). The protocol used was a modi-
fied method of Marzella and Glaumann (1980) (Marzella 
& Glaumann, 1980). Ultrathin slices were prepared using 
the ultramicrotome Leica EM UC7. Photographs were 
taken using the transmission electron microscope Tecnai 
G2 Spirit (FEI Company, USA).
Hematology analysis. Blood morphology and bio-
chemical parameters were analyzed for 12 animals using 
the hematological analyzer Cobas e 411 (Roche). Immu-
noenzymatic assay methods with appropriate reagent kits 
were used. The Elecsys Vitamin D Total test, involving 
the “ECLIA” electrochemiluminescence method, was 
used for determination of 25-hydroxyvitamin D levels 
in hamster serum. Hamster blood was sampled from the 
beating heart into vials with K3EDTA. Blood smears 
were performed for all samples, and stained using the 
Pappenheim method (May Grunwald-Giemza, AQUA-
MED, Kraków, Poland). Microscopic analysis of blood 
cells was carried out using immersion under magnifica-
tion of 1000x, and calculated using Shilling’s formula 
(Krawczyński & Osiński, 1967).
Statistics and data analysis. Statistica12® software 
(StatSoft, Tulsa, USA) was used to analyze the experi-
mental results. The Syrian golden hamsters were divided 
into fully randomized groups. One-way ANOVA, U-test 
and Fisher test were performed on a needs basis. During 
analysis, all data were correlated together to investigate 
the possible reasons for data heterogeneity.
RESULTS
Animal behavior and macroscopic observation during 
necropsy
All animals treated with a high dose of calcitriol were 
nervous and overreactive. During they long-term stay 
in the animal facility, untreated animals were calm and 
well-adjusted to handlers. In contrast, agitated and ag-
gressive behavior towards handlers was observed after 
a single dose of calcitriol (0.717 µg/kg). Animal weight 
has not changed throughout the experiment. The quanti-
fied information about the change in hamster behavior 
after calcitriol treatment in comparison to the control is 
shown in Table 1.
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In animals without calcitriol treatment, as well as in 
the group of hamsters injected with 50 nM calcitriol, 
there were no macroscopic changes found in the liv-
er. However, after the highest dose of calcitriol, cystic 
changes in the liver were observed at the macroscopic 
level. There were no changes in the liver weight between 
the control and experimental groups. Statistical analysis 
(Anova univariate) showed no significant difference in 
the weight of the livers of animals from individual ex-
perimental groups. Mean liver weight values are present-
ed in the Supplementary Fig. S2 (at www.actabp.pl).
Blood and serum effects
To find an explanation for observed behavior changes, 
blood samples were analyzed. The levels of Ca (calcium), 
P (phosphate) and Mg (magnesium) were unaffected by 
calcitriol treatment (Fig. S3, Table S1 at www.actabp.pl). 
No significant changes in the hematological parameters 
were found (Fig. S3, Table S2 and S3 at www.actabp.
pl). Red blood cell parameters and leukocyte characteris-
tics were within the normal range for a healthy hamster 
(Weiss & Wardrop, 2010; Suckow et al., 2012), although 
they were at the upper limit for each group. Mean val-
ues are presented in the Supplementary Fig. S3 (at www.
actabp.pl).
Level of calcidiol in the blood
To compare our results with the gold-standard clinical 
test for vitamin D body level, the calcidiol blood concen-
tration was measured. The level of 25(OH)D3 was meas-
ured in the hamster blood 3 days after the single, intra-
peritoneal injection of calcitriol. No significant changes 
were registered between the vehicle control (14.96±2.24 
ng/ml) and experimental groups that received 50 and 
200 nM of calcitriol (16.33±2.97 and 15.26±4.70 ng/ml).
Biochemical effects
Liver toxicity was characterized by biochemical param-
eters. There was only a slight increase in the alanine ami-
notransferase (ALT) after calcitriol treatment, which was 
Table 1. The table presents behavioral changes and macroscopic changes in the liver according to the calcitriol doses. 
The behavior is presented on a scale of 0–1, where 0 = calmness; 1 = aggressiveness. Changes in the liver are shown on a scale of 0–2, 
where 0 = no change; 1 = small cysts; 2 = large cysts. Average values±SD illustrating the liver changes for calcitriol doses 0nM, 50 nM and 
200 nM were 0±0, 0±0 and 1.25±0.50, respectively. The ANOVA test showing statistical significance for the highest dose of calcitriol as 
compared with the control group was p=0.024.
Calcitriol dose [nM] Animal code Behavior Changes on the liver
0
1 0 0
2 0 0
3 0 0
4 0 0
50
5 0 0
6 0 0
7 0 0
8 0 0
200
9 1 1
10 1 1
11 1 1
12 1 2
Table 2. The mean values (n=4) for liver function tests, depending on the dose of calcitriol (A). 
The chart presents the dependence of aspartate aminotransferase (AST) levels on the calcitriol dose for individual animals.
Dose of calcitriol  [nM]
Parameters
ALT [U/I] AST [U/I] GGTP [U/I]
0 38.00±4.8 41.5±11.21 1.25±0.96
50 42.75±20.22 55.5±18.91 0.75±1.5
200 43.25±9.54 99.25±56.81 0.5±0.58
Figure 1. The increase in AST due to calcitriol treatment dose 
was estimated to have the following effect: F(2, 9)=2.93520, 
p=0.10439, and significant intercept (p=0.0001). 
The point labels indicate the animal code. A considerable hetero-
geneity of AST values was observed for hamsters treated with 200 
nM calcitriol solution. The variances differed between the calcitriol 
dose groups (p-value of Fisher test for dose 50 nM and 200 nM 
relative to control was 0.1048 and 0.6571, respectively, which in-
dicated a statistical difference between variances of the individual 
samples).
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statistically insignificant. An increase in the aspartate ami-
notransferase (AST) values was observed for two experi-
mental groups as compared with the untreated control 
(ANOVA intercept p=0.0001). There was a higher than 
a two-fold increase in the mean AST values between the 
control group and the group treated with the highest 
dose of calcitriol. The levels of gamma-glutamyl trans-
peptidase (GGTP) were reduced in experimental groups 
in comparison to the control, however, the changes were 
not statistically significant. Mean values ± S.D. of liver 
function tests are presented in Table 2. The dependence 
of AST levels on the administered calcitriol dose in in-
dividual animals is presented in Fig. 1. The above analy-
sis indicates an enhanced liver activity (Supplementary 
Fig. S4 at www.actabp.pl).
Ultrastructural effects in the liver after calcitriol 
treatment
Numerous normal organelles, with proper structure 
and size, were observed in the hepatocytes of the un-
treated animals. Normal nucleus, cisterns of rough en-
doplasmic reticulum, primary lysosomes, single vacuoles 
and mitochondria were observed (Fig. 2A and 2B).
In comparison, the ultrastructure of hepatocytes ob-
tained from animals treated with calcitriol at 50 nM has 
changed (Fig. 2C and 2D). Specifically, there was a slight 
increase in the number and size of mitochondria. More-
over, a distinct enlargement of the lysosomal system was 
seen (Fig. 2C and 2D) and there was formation of au-
tophagic vacuoles at different stages of development.
The ultrastructure of hepatocytes from the livers of 
hamsters treated with 200 nM was substantially changed 
(Fig. 2E and 2F). Mitochondria were more numer-
ous, enlarged and with a changed structure. Moreover, 
the mitochondria were often surrounded by the mem-
brane of the endoplasmic reticulum, indicating progress-
ing vacuolization. Other findings included an increased 
number of lysosomes, numerous autophagic vacuoles, 
and a slight swelling of the rough endoplasmic reticulum 
(Fig. 2E).
Ultrastructural effects in the kidney after calcitriol 
treatment
Normal organelles of proper size and structure were 
seen in the kidney cells obtained from untreated ani-
mals. Figs 3A and 3B show the nucleus, mitochondria, 
primary lysosomes, Golgi apparatus and single vacuoles. 
The low dose of calcitriol (50 nM) already caused an in-
crease in the number and size of mitochondria, as well 
as the presence of many ribosomes and polyribosomes 
(Figs 3C and 3D). Calcitriol also led to a distinctive in-
crease of the lysosomal compartment, and to generation 
Figure 2. Fragments of a hepatocyte from liver (A, B) of an untreated animal, (C, D) of a hamster treated with 50 nM, (E, F) of a ham-
ster treated with 200 nM. 
Nucleus (N), mitochondria (M), rough endoplasmic reticulum (ER), single autophagic vacuoles (AV), primary lysosomes (LP), peroxisomes 
(P), secondary lysosomes (LS), polyribosomes (Pr), cellular membrane (CM), and bile duct (BC) were seen in the cytoplasm. Magnification 
11 500× (A–F).
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of various autophagic vacuoles at different stages of de-
velopment. Close to the nucleus, more swollen Golgi ap-
paratus cisterns were detected.
The higher dose of calcitriol (200 nM) induced sub-
stantial changes in the ultrastructure of kidney cells in 
comparison to the control group. Both, the size and 
number of mitochondria increased, and shortened mi-
tochondrial cristae were observed. Mitochondrial swell-
ing was also seen (Fig. 3E). A substantial increase in the 
number of lysosomes, and numerous various autophagic 
vacuoles, as well as autophagolysosomes was characteris-
tic for autophagy. Cellular response in the kidney to the 
increased dose of calcitriol is shown in Figs 3E and F, 
presenting the enhanced lysosomal system and increased 
number of peroxisomes.
DISCUSSION
The most important message from our study is vita-
min D toxicity (unrelated to the calcium and magnesi-
um blood levels) in older Syrian golden hamsters. The 
observed effect was demonstrated by changes on the 
macro- and micro-scale (e.g. liver cysts, increase in the 
number and size of mitochondria in livers and kidneys), 
and by the pain-related behavioral changes.
We found that the observed nervousness and hyperac-
tivity in animals had been related to the highest injected 
dose of calcitriol (200 nM). The reasons behind such be-
havior were not clear. However, it appeared to be a typi-
cal behaviour of Syrian golden hamsters in response to 
pain. Additionally, during the necropsy examination, sig-
nificant changes in liver morphology were observed (e.g. 
cysts). Moreover, our further analysis strongly indicated 
the presence of hepatotoxic effects of calcitriol. There-
fore, we postulate that severe liver pain after a high dose 
of calcitriol may be responsible for the observed chang-
es in animal behavior. Additionally, liver damage might 
have induced the itching of the skin, which would ex-
plain the nervousness of the animals while handling.
Due to the fact that several steps of vitamin D me-
tabolism, and its binding to specific proteins, depend 
on magnesium as a cofactor (Gröber et al., 2015), ad-
ministration of high doses of vitamin D leads to deple-
tion of magnesium (Reddy & Edwards, 2017). However, 
in the current study, tests did not reveal a reduction in 
magnesium levels in any of the animal groups. Due to a 
common problem with the availability of tests determin-
ing the exact level of magnesium, the results could have 
been overestimated. It should be noted though, that 
even if the results represent normal levels of magnesium 
Figure 3. Fragments of the kidney cells (A, B) of an untreated animal, (C, D) of a hamster treated with 50 nM, (E, F) of a hamster 
treated with 200 nM. 
Nucleus (N), mitochondria (M), single autophagic vacuoles (AV), primary lysosomes (LP), Golgi apparatus (AG), polyribosomes (Pr), cell 
membrane (CM), endoplasmic reticulum (ER), peroxisomes (P.) and microvilli (MC). Magnification 8 200× (A, B, D–F), 9 900× (C).
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in plasma, there may still be an intracellular deficiency of 
it (Reddy & Edwards, 2017).
Based on vitamin D metabolism pathway in the 
body, the finding of no significant changes in calcidiol 
(25(OH)D3) blood concentration in all of experimental 
groups may be treated as a proof of concept for our 
experiment, where calcitriol (1,25(OH)2D3) was injected 
into the animals. The level of 25(OH)D3 is related to 
the liver metabolism, whereas 1,25(OH)2D3 blood level 
is associated with kidney function, and depends on the 
25(OH)D3 level. In our case, the assumption can be 
made that the self-produced 1,25(OH)2D3 is similar in 
all experimental groups (based on 25(OH)D3 levels), and 
the difference in calcitriol levels is only due to the in-
jected amount.
However, the morphological defects in the liver ap-
pear to be confirmed by selected biochemical parame-
ters only. Thus, a more than two-fold increase was ob-
served for the AST levels in hamsters given 200 nM of 
calcitriol as compared with the untreated group, which 
might indicate liver damage resulting from the admin-
istration of calcitriol, considering the function of AST. 
ALT and AST are enzymes that are found especially 
in the liver and skeletal muscles, but in other organs 
as well. Elevated enzyme levels are seen, inter alia, in 
hamsters with hepatic necrosis, affected hepatocytes or 
liver neoplasia and metabolic alterations (Suckow et al., 
2012). The ratio of AST to ALT is more clinically use-
ful, and it is calculated if the normal ranges for those 
enzymes are exceeded. Ratios higher than 1 indicate 
liver disease, while ratios greater than 2 are observed 
in toxic damage, e.g. in alcoholic hepatitis (Gowda 
et al., 2009). Interestingly, the mean ratio of AST to 
ALT in animals injected with 200 nM of calcitriol was 
close to 2, while for the control group it was almost 
1. Those results can be explained by two factors: (1) 
age of the tested animals, and (2) ethanol concentra-
tion in the injected solution. Namely, hamsters metab-
olize ethanol very well and very quickly. This serves 
as protection against liver damage, and most probably 
results from an evolutionary adaptation associated with 
the necessity of consuming fermented grains stored in 
damp burrows (McPherson & Van Hoosier, 1987). Liv-
er changes can be also associated with aging (Suckow 
et al., 2012). However, the effect of aging was exclud-
ed, because all hamsters in both, the control group and 
the experimental groups, were of similar age, and in 
animals without calcitriol, no changes in the liver were 
observed. Although in the control group the AST level 
was slightly raised in comparison to young animals, a 
significant increase in the level of the parameters was 
observed only after calcitriol administration. Therefore, 
we postulate that the observed liver damage is directly 
related to calcitriol supplementation.
Furthermore, liver damage is usually accompanied by 
an increase in the gamma-glutamyl transpeptidase levels 
(Gowda et al., 2009). However, the study presented here 
reveals a slightly reduced, but statistically not significant 
effect observed with increased doses of calcitriol. This 
suggests a lack of bile duct damage resulting from the 
calcitriol doses used.
The possibility of observing changes in organs under 
the influence of vitamin D is also interesting in view of 
the results presented in the publication of McCullough 
and coworkers in 2010 (McCullough et al., 2010). Re-
sults from epidemiologic studies presented in that work 
showed that a high dose of 25(OH)D was associated 
with a two-fold higher risk of developing pancreatic can-
cer (McCullough et al., 2010).
The recognised toxicity of vitamin D is hypercalcemia 
(Slominski et al., 2010, 2011; Wang et al., 2012; Cheng 
et al., 2014). However, the presented analyses demon-
strate a lack of effect on calcium levels. According to 
the literature, calcium levels for healthy hamsters should 
fall within the range of 5.3–12.0 mg/dl (Suckow et al., 
2012); the calcium levels obtained in both, the control 
and experimental groups, were slightly above that limit. 
For the control group, the mean value was 13.97 ± 0.97, 
while for the groups treated with 50 nM and 200 nM 
of calcitriol, it was 13.80 ± 0.85 and 14.53 ± 1.23, respec-
tively, hence no hypercalcemia could be observed after 
the administration of calcitriol in the tested hamsters. 
The level of Ca in serum could be affected by the age of 
hamsters used in the experiment. It is known that older 
animals may present with calcium metabolism disorders, 
which are the result of hormonal disturbances related 
to age, especially in females (Yeh et al., 2013). Finally, 
standardization of the Ca assay used in the study may 
be different from those previously reported (Suckow et 
al., 2012), thus leading to a higher reading in the control 
values. Nevertheless, the data we present clearly indicate 
a lack of effect of the injected calcitriol doses on plasma 
calcium and phosphate levels.
Ultrastructural examination of the livers demonstrat-
ed an effect of calcitriol. Namely, normal organelles 
were observed in the hepatocytes of the untreated an-
imals, while changes were seen in the hepatocytes ob-
tained from animals treated with calcitriol dosed at 50 
nM and 200 nM. For example, generation of various 
autophagic vacuoles at different stages of development, 
and enlargement of the lysosomal system, following the 
administration of the 50 nM calcitriol dose indicate the 
induction of autophagy as an adaptive cellular response 
to calcitriol treatment. The higher dose of calcitriol also 
led to the induction of structures typical of autophagy, 
i.e. primary and secondary lysosomes, and autophagic 
vacuoles (containing material at various stages of deg-
radation). The observed effects could indicate distress 
induced by calcitriol on cellular metabolism, exempli-
fied by the changes in mitochondria, and lysosomal ac-
tivities.
Ultrastructural effects after calcitriol treatment were 
also investigated in the kidneys. While kidney cells 
from untreated animals showed normal organelles 
(proper size and structure), the same structures were 
altered in animals treated with calcitriol. Following in-
jection of the lower dose of calcitriol, the changes in-
dicated induction of autophagy as an adaptive response 
of kidney cells to calcitriol. However, effects after the 
dose of 200 nM, such as swelling of the mitochondria, 
suggested a metabolic effect in response to calcitriol. 
Cellular response in the kidneys to an increased dose 
of calcitriol consists of defense mechanisms’ activation. 
The changes in the kidneys might be secondary to an 
inadequate liver metabolism of calcitriol.
To eliminate other reasons for the observed change 
in animal behavior, an alternative hypothesis was test-
ed. That is why the level of available magnesium, called 
‘the sedative ion’ (DiSilvestro, 2005), was measured. In 
magnesium deficiency, the activation of calcium channels 
decreases, leading to an increase in the calcium concen-
tration in the cell, and later to a reduced axon stimula-
tion threshold, which then results in an increase in neu-
romuscular excitability (Mawri et al., 2017). However, in 
our experiment, no significant differences in magnesium 
and calcium levels were detected.
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CONCLUSION
Our results indicate that the tested doses of calcitriol 
may lead to acute effects on the liver and kidneys. The 
hepatotoxic effect of calcitriol in Syrian golden ham-
ster can be painful, and seems to be a primary cause of 
changes in the animal behavior.
Our findings suggest that animal age may be an im-
portant factor for vitamin D toxicity due to acute effects 
on the liver, without related changes in the calcium level. 
The significant changes in animal behavior were related 
to calcitriol uptake.
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